AVITA MEDICAL INC (AVH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AVH

AVH - AVITA MEDICAL INC

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.88
Index: ALL-ORDS

Avita Medical is developing and marketing a range of regenerative skin products. It is headquartered in California and listed on the ASX and NASDAQ.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.27

11 Sep
2025

-0.015

OPEN

$1.29

-1.17%

HIGH

$1.30

439,617

LOW

$1.27

TARGET
$1.75 37.8% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
AVH: 1
Title FY25
Forecast		 FY26
Forecast
EPS (cps) - 101.2 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 201920202021202220232024
EPS Basic xxxxxxxxxxxxxxx-72.5
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx97.4 M
Book Value Per Share xxxxxxxxxxxxxxx5.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-74.2 M
Net Profit Margin xxxxxxxxxxxxxxx-96.26 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201920202021202220232024
Return on Capital Employed xxxxxxxxxxxxxxx-236.89 %
Return on Invested Capital xxxxxxxxxxxxxxx-88.11 %
Return on Assets xxxxxxxxxxxxxxx-64.14 %
Return on Equity xxxxxxxxxxxxxxx-236.89 %
Return on Total Capital xxxxxxxxxxxxxxx-79.48 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-88.1 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201920202021202220232024
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx73 M
Total Debt xxxxxxxxxxxxxxx74 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx58 M
Price To Book Value xxxxxxxxxxxxxxx77.08

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201920202021202220232024
Capex xxxxxxxxxxxxxxx14.1 M
Capex % of Sales xxxxxxxxxxxxxxx14.53 %
Cost of Goods Sold xxxxxxxxxxxxxxx14 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx169 M
Research & Development xxxxxxxxxxxxxxx31 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

5

xxxxxxxxx xx xxxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

11/08/2025

1

Speculative Buy

$2.00

57.48%

Morgans has repeated its assessment from Friday: Avita Medical's 2Q25 report represents a significant miss versus expectations.

Morgans points out there was no sales growth on the quarter as delays and complications continue to secure reimbursement from the regional Medicare contractors.

Management has been forced to make large downgrades to guidance, and pushed guidance around profitability to the middle of next year.

The broker finds solace in the fact management has successfully rolled through cost-base reductions, as planned, decreasing the net loss with more to come in 3Q.

Alas, Morgans now also believes another capital raising will be necessary to successfully lead this company to profitability.

Reduced forecasts have pulled back the price target to $2 from $3.76 prior. Speculative Buy rating retained with the comment that both balance sheet and execution risks have increased.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -40.47 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -18.14 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

13/08/2025

5

Underweight

$1.25

-1.57%

Avita Medical cut its 2025 guidance by -24% to US$76m–US$81m, with 2Q2025 revenue of US$18.4m missing Wilsons' forecast by -20% and consensus by -23% due to CMS' coding and payment practices being "dislocated" for Recell over the quarter.

Providers lowered Recell re-orders as a result of denial of consistent payments, which, as the analyst explains, is “understandable.” Medicare Administrative Contractors are due to restart Recell claims adjudication and payments during 3Q2025.

Due to the deferral in GAAP net profit after tax, now targeted for 3Q2026, and cash flow breakeven in 2Q2026, with US$42m in debt moved to current liabilities, Wilsons estimates a capital requirement of US$75m to repay debt and keep Avita's assets ongoing.

Underweight rating retained. Target price falls another -35% to $1.25, Wilsons bemoans.

FORECAST
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -28.38 cents.
Wilsons forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -16.13 cents.
Access Extra Coverage Research History >

AVH STOCK CHART

FNArena News on AVH

1
In Brief: NRW Holdings, Aroa Biosurgery, Online Retail Winners

10:00 AM - Weekly Reports
2
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View
3
Rudi’s View: A Glass Half-Full Outlook

Sep 03 2025 - Rudi's View
4
Weekly Ratings, Targets, Forecast Changes – 22-08-25

Aug 25 2025 - Weekly Reports
5
Rudi’s View: Early August Signals & Observations

Aug 20 2025 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
2
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
3
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
4
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
5
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
6
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
7
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
8
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
9
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
10
CSL Shares Breaking Free

Jul 23 2024 - Technicals